Business Context and Reporting Period
Company: uniQure N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Accounting Standards: International Financial Reporting Standards (IFRS)
Reporting Currency: Euro (€)
uniQure is a biopharmaceutical company focused on developing gene therapies for liver/metabolic, central nervous system (CNS), and cardiovascular diseases. The company's only approved product is Glybera (for LPLD), which received marketing authorization in the European Union under exceptional circumstances in 2012. Commercialization of Glybera began in September 2015. The company is heavily reliant on strategic collaborations, most notably with Bristol-Myers Squibb (BMS) and Chiesi Farmaceutici, for funding and commercialization.
Key Financial Metrics (Year Ended Dec 31, 2015)
| Metric | 2015 (€ millions) | 2014 (€ millions) |
|---|---|---|
| Total Revenues | 9.4 | 4.7 |
| Net Loss | (71.5) | (37.0) |
| Operating Result | (68.4) | (33.8) |
| Research & Development Expenses | (46.8) | (33.9) |
| Cash and Cash Equivalents | 203.5 | 53.2 |
| Total Debt | 20.3 | 17.3 |
| Shareholders' Equity | 119.5 | 43.1 |
Revenue Breakdown (2015): License revenues (€2.9M), Collaboration revenues (€6.3M), and Product sales (€0.3M).
Loss Per Share: €3.24 (Basic and Diluted).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 101% year-over-year, driven by the amortization of upfront payments from the BMS collaboration and the first commercial sales of Glybera.
- Increased Losses: Net loss widened significantly from €37.0M to €71.5M. This was primarily due to a €11.6M impairment loss on intangible assets related to Glybera and increased R&D expenses.
- Impairment Loss: In Q3 2015, the company recorded a €11.6M impairment loss following disclosures from partner Chiesi regarding reimbursement challenges for Glybera in certain European markets (specifically France and Germany).
- Liquidity Improvement: Cash and cash equivalents surged from €53.2M to €203.5M, fueled by a follow-on public offering (€77.9M net proceeds) and equity investments from BMS (€58.5M).
- Debt Structure: Total debt increased to €20.3M, consisting of borrowings under a venture debt facility with Hercules Technology Growth Capital, Inc.
Guidance, Outlook, and Risks
Outlook and Funding: Management expects expenses to increase substantially in the coming years as the company advances clinical trials for AMT-060 (Hemophilia B), AMT-110 (Sanfilippo B), and S100A1 (Heart Failure). The company believes its cash position as of December 31, 2015, is sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional funding in the future, which may not be available on acceptable terms.
Key Risks and Contingencies:
- Commercialization of Glybera: Reimbursement for Glybera remains uncertain. France denied reimbursement, and Germany restricted it to hospital-only sales. The company is required to complete post-approval clinical trials; failure to do so could result in withdrawal of marketing authorization.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of sufficient segregation of duties within the finance team. Remediation efforts are ongoing.
- Dependence on Collaborators: The company relies on BMS for cardiovascular development and Chiesi for Glybera commercialization. Failure of these partners to meet milestones or commercialize products would materially harm the company.
- Regulatory Approval: The company has not received FDA approval for any products. Glybera is not being pursued for U.S. approval. Future products face significant regulatory hurdles, particularly regarding gene therapy safety and manufacturing comparability.
Investor Verification Checklist
- Reimbursement Status: Verify current pricing and reimbursement decisions for Glybera in key EU markets (Germany, France, UK) and the impact on projected cash flows.
- Impairment Assumptions: Review the specific assumptions used to calculate the €11.6M impairment loss regarding Glybera's future cash flows.
- Internal Control Remediation: Monitor the progress of remediation measures for the material weakness in internal controls over financial reporting.
- BMS Collaboration Milestones: Track the designation of new targets by BMS and the achievement of regulatory milestones to trigger future payments.
- Cash Burn Rate: Assess the runway of the €203.5M cash balance against the projected increase in R&D and SG&A expenses, particularly regarding the Lexington, MA manufacturing facility.
- Debt Covenants: Review the covenants associated with the Hercules loan facility, specifically the minimum cash balance requirements and restrictions on additional indebtedness.